FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2884800903> ?p ?o ?g. }

• W2884800903 endingPage "31065" @default.
• W2884800903 startingPage "31045" @default.
• W2884800903 abstract "// Andrea González-Morales 1, 2, 3 , Aintzane Zabaleta 2, 4 , Elizabeth Guruceaga 2, 5 , Marta M. Alonso 2, 6, 7 , Marc García-Moure 2, 6, 7 , Joaquín Fernández-Irigoyen 1, 2, 3, * , Enrique Santamaría 1, 2, 3, * 1 Clinical Neuroproteomics Group, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), Irunlarrea, Pamplona, Spain 2 IDISNA, Navarra Institute for Health Research, Pamplona, Spain 3 Proteored-ISCIII, Proteomics Unit, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), Irunlarrea, Pamplona, Spain 4 Oncohematology Area, University Hospital of Navarra, Center for Applied Medical Research, CIBERONC, Pamplona, Spain 5 Bioinformatics Unit, Center for Applied Medical Research, University of Navarra, Pamplona, Spain 6 Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, Pamplona, Spain 7 Department of Pediatrics, University Hospital of Navarra, Pamplona, Spain * These authors share senior authorship Correspondence to: Enrique Santamaría, email: esantamma@navarra.es Keywords: adenovirus; Delta-24RGD infection; proteomics; glioma Received: February 06, 2018     Accepted: June 22, 2018     Published: July 24, 2018 ABSTRACT Glioblastoma multiforme (GBM) is the most common and aggressive type of malignant glioma. Oncolytic adenoviruses are being modified to exploit the aberrant expression of proteins in tumor cells to increase the antiglioma efficacy. E1A mutant adenovirus Delta-24-RGD (DNX-2401) has shown a favorable toxicity profile and remarkable efficacy in a first-in-human phase I clinical trial. However, the comprehensive modulation of glioma metabolism in response to Delta-24-RGD infection is poorly understood. Integrating mass spectrometry based-quantitative proteomics, physical and functional interaction data, and biochemical approaches, we conducted a cell-wide study of cytosolic, nuclear, and secreted glioma proteomes throughout the early time course of Delta-24-RGD infection. In addition to the severe proteostasis impairment detected during the first hours post-infection (hpi), Delta-24-RGD induces a transient inhibition of signal transducer and activator of transcription 3 (STAT3), and transcription factor AP-1 (c-JUN) between 3 and 10hpi, increasing the nuclear factor kappa B (NF-κB) activity at 6hpi. Furthermore, Delta-24-RGD specifically modulates the activation dynamics of protein kinase C (PKC), extracellular signal–regulated kinase 1/2 (ERK1/2), and p38 mitogen-activated protein kinase (p38 MAPK) pathways early in infection. At extracellular level, Delta-24-RGD triggers a time –dependent dynamic production of multitasking cytokines, and chemotactic factors, suggesting potential pleiotropic effects on the immune system reactivation. Taken together, these data help us to understand the mechanisms used by Delta-24-RGD to exploit glioma proteome organization. Further mining of this proteomic resource may enable design and engineering complementary adenoviral based-vectors to increase the specificity and potency against glioma." @default.
• W2884800903 created "2018-08-03" @default.
• W2884800903 creator A5005329272 @default.
• W2884800903 creator A5038432727 @default.
• W2884800903 creator A5043296656 @default.
• W2884800903 creator A5060174518 @default.
• W2884800903 creator A5075567314 @default.
• W2884800903 creator A5076205150 @default.
• W2884800903 creator A5090362608 @default.
• W2884800903 date "2018-07-24" @default.
• W2884800903 modified "2023-09-27" @default.
• W2884800903 title "Spatial and temporal proteome dynamics of glioma cells during oncolytic adenovirus Delta-24-RGD infection" @default.
• W2884800903 cites W1538993303 @default.
• W2884800903 cites W1545152283 @default.
• W2884800903 cites W182541892 @default.
• W2884800903 cites W1848702643 @default.
• W2884800903 cites W1970666372 @default.
• W2884800903 cites W1972685881 @default.
• W2884800903 cites W1990705041 @default.
• W2884800903 cites W1991366673 @default.
• W2884800903 cites W1991862650 @default.
• W2884800903 cites W1992215859 @default.
• W2884800903 cites W1993457485 @default.
• W2884800903 cites W1996239879 @default.
• W2884800903 cites W2021925807 @default.
• W2884800903 cites W2023010129 @default.
• W2884800903 cites W2035755400 @default.
• W2884800903 cites W2036926672 @default.
• W2884800903 cites W2040486656 @default.
• W2884800903 cites W2041267103 @default.
• W2884800903 cites W2042943782 @default.
• W2884800903 cites W2052775071 @default.
• W2884800903 cites W2063348489 @default.
• W2884800903 cites W2069228161 @default.
• W2884800903 cites W2072236945 @default.
• W2884800903 cites W2076485183 @default.
• W2884800903 cites W2085206357 @default.
• W2884800903 cites W2089768104 @default.
• W2884800903 cites W2101781016 @default.
• W2884800903 cites W2103662370 @default.
• W2884800903 cites W2103810198 @default.
• W2884800903 cites W2106899106 @default.
• W2884800903 cites W2106989835 @default.
• W2884800903 cites W2109767323 @default.
• W2884800903 cites W2110275053 @default.
• W2884800903 cites W2110592777 @default.
• W2884800903 cites W2115129497 @default.
• W2884800903 cites W2117210608 @default.
• W2884800903 cites W2124476064 @default.
• W2884800903 cites W2132532698 @default.
• W2884800903 cites W2132915029 @default.
• W2884800903 cites W2133473226 @default.
• W2884800903 cites W2147823227 @default.
• W2884800903 cites W2151513527 @default.
• W2884800903 cites W2155109817 @default.
• W2884800903 cites W2157942810 @default.
• W2884800903 cites W2158681922 @default.
• W2884800903 cites W2163758870 @default.
• W2884800903 cites W2164669575 @default.
• W2884800903 cites W2165073006 @default.
• W2884800903 cites W2165871546 @default.
• W2884800903 cites W2165922840 @default.
• W2884800903 cites W2168412437 @default.
• W2884800903 cites W2235247229 @default.
• W2884800903 cites W2463195069 @default.
• W2884800903 cites W2528277111 @default.
• W2884800903 cites W2552210919 @default.
• W2884800903 cites W2572711501 @default.
• W2884800903 cites W2581413054 @default.
• W2884800903 cites W2585659713 @default.
• W2884800903 cites W2588305202 @default.
• W2884800903 cites W2620081458 @default.
• W2884800903 cites W2765082845 @default.
• W2884800903 cites W2787278337 @default.
• W2884800903 cites W4211238487 @default.
• W2884800903 doi "https://doi.org/10.18632/oncotarget.25774" @default.
• W2884800903 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6089549" @default.
• W2884800903 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30123426" @default.
• W2884800903 hasPublicationYear "2018" @default.
• W2884800903 type Work @default.
• W2884800903 sameAs 2884800903 @default.
• W2884800903 citedByCount "7" @default.
• W2884800903 countsByYear W28848009032019 @default.
• W2884800903 countsByYear W28848009032020 @default.
• W2884800903 countsByYear W28848009032021 @default.
• W2884800903 countsByYear W28848009032022 @default.
• W2884800903 crossrefType "journal-article" @default.
• W2884800903 hasAuthorship W2884800903A5005329272 @default.
• W2884800903 hasAuthorship W2884800903A5038432727 @default.
• W2884800903 hasAuthorship W2884800903A5043296656 @default.
• W2884800903 hasAuthorship W2884800903A5060174518 @default.
• W2884800903 hasAuthorship W2884800903A5075567314 @default.
• W2884800903 hasAuthorship W2884800903A5076205150 @default.
• W2884800903 hasAuthorship W2884800903A5090362608 @default.
• W2884800903 hasBestOaLocation W28848009031 @default.
• W2884800903 hasConcept C121608353 @default.
• W2884800903 hasConcept C126322002 @default.
• W2884800903 hasConcept C143998085 @default.

• next